These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 19178029)
1. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Machado V; Cabral A; Monteiro P; Gonçalves L; Providência LA Rev Port Cardiol; 2008 Oct; 27(10):1277-96. PubMed ID: 19178029 [TBL] [Abstract][Full Text] [Related]
2. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. de Nigris F; Rienzo M; Schiano C; Fiorito C; Casamassimi A; Napoli C Eur J Cancer; 2008 Feb; 44(3):334-40. PubMed ID: 18194856 [TBL] [Abstract][Full Text] [Related]
3. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256 [TBL] [Abstract][Full Text] [Related]
6. Carvedilol: just another Beta-blocker or a powerful cardioprotector? Carreira RS; Monteiro P; Gon Alves LM; Providência LA Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):257-66. PubMed ID: 17378771 [TBL] [Abstract][Full Text] [Related]
7. 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. El-Bakly WM; Louka ML; El-Halawany AM; Schaalan MF Cancer Chemother Pharmacol; 2012 Dec; 70(6):833-41. PubMed ID: 23014738 [TBL] [Abstract][Full Text] [Related]
10. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Ludke AR; Al-Shudiefat AA; Dhingra S; Jassal DS; Singal PK Can J Physiol Pharmacol; 2009 Oct; 87(10):756-63. PubMed ID: 19898559 [TBL] [Abstract][Full Text] [Related]
11. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y Toxicology; 2010; 274(1-3):18-26. PubMed ID: 20452391 [TBL] [Abstract][Full Text] [Related]
12. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575 [TBL] [Abstract][Full Text] [Related]
13. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Vejpongsa P; Yeh ET J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180 [TBL] [Abstract][Full Text] [Related]